Habituelle Abortneigung: Evidenzbasierte Diagnostik und Therapie

Zusammenfassung

Etwa 1–3 % aller Paare mit Kinderwunsch erleiden wiederholte Fehlgeburten. Aufgrund des steigenden mütterlichen Alters bei der ersten Schwangerschaft, insbesondere in Westeuropa, gibt es eine zunehmende Tendenz, bereits Frauen mit 2 Fehlgeburten einer ausführlichen Diagnostik zu unterziehen, obwohl die WHO mindestens 3 aufeinanderfolgende Aborte als rezidivierendes Abortgeschehen definiert. Dabei sollte eine sinnvolle Abklärung primär alle relevanten Abortursachen umfassen, gleichzeitig aber auch kosteneffektiv sein sowie zu evidenzbasierten, therapeutischen Konsequenzen führen. Dies ist insbesondere vor dem Hintergrund der Fülle der vorliegenden aktuellen Daten und möglichen Therapieoptionen von entscheidender Bedeutung. Experimentelle therapeutische Ansätze sollten nur unter Studienbedingungen erprobt werden.

Abstract

About 1–3 % of all couples suffer recurrent miscarriages during their childbearing years. Due to the increase in maternal age at the first pregnancy, especially in Western Europe, there is a tendency to carry an extensive diagnostic work-up after two miscarriages, although the WHO definition of recurrent miscarriage defines it as three or more consecutive pregnancy losses. Causal clarification should primarily focus on possible risk factors for miscarriages while being cost-effective and leading to promising therapeutic consequences. In view of the large number of studies and therapeutic options, an evidence-based concept for diagnostic and therapeutic guidelines on recurrent miscarriages is essential. New treatment strategies need to be confirmed in large randomized placebo-controlled trials.

Schlüsselwörter

habituelle Aborte - evidenzbasierte Diagnostik - Therapie

Key words

recurrent miscarriages - evidence‐based diagnostic - treatment strategies

Literatur

• 1 Bohlmann M K, Schauf B, Luedders D W et al. Aktuelles zur rationellen Diagnostik und Therapie habitueller Frühaborte.  Geburtsh Frauenheilk. 2007;  67 217-227
• 2 Stirrat G M. Recurrent miscarriage.  Lancet. 1990;  336 673-675
• 3 Franssen M T, Korevaar J C, Leschot N J et al. Selective chromosome analysis in couple with two or more miscarriages: case-control study.  BMJ. 2005;  331 137-141
• 4 Hinney B. Habituelle Abortneigung.  Gynäkologe. 2007;  40 113-127
• 5 Goldenberg M, Sivan E, Sharabi Z et al. Reproductive outcome following hysteroscopic management of intrauterine septum and adhesions.  Hum Reprod. 1995;  10 2663-2665
• 6 Hickok L R. Hysteroscopic treatment of the uterine septum: a clinician's experience.  Am J Obstet Gynecol. 2000;  182 1414-1420
• 7 Li T C, Makris M, Tomsu M et al. Recurrent miscarriage: aetiology, management and prognosis.  Human Reprod Update. 2002;  8 463-481
• 8 Hornemann A, Luedders D W, Kumbartski M et al. Anatomische Ursachen habitueller Aborte.  Gynäkologe. 2009;  42 11-16
• 9 Plesinac S, Plecas D, Babovic I. Influence of uterine myomas on course and outcome of pregnancy.  Geburtsh Frauenheilk. 2006;  66 674-676
• 10 Steck T, Bussen S, Marzusch K. Strategien zur Abortprophylaxe bei einer Vorgeschichte mit wiederholten Aborten. II. Infektionen, metabolische und endokrine Störungen, Schadstoffe und Gerinnungsdefekte.  Fertilität. 1997;  13 17-26
• 11 Stray-Pedersen B, Stray-Pedersen S. Etiologic factors and subsequent reproductive performance in 195 couples with a prior history of habitual abortion.  Am J Obstet Gynecol. 1984;  148 140-146
• 12 Abalovich M, Gutierrez S, Alcaraz G et al. Overt and subclinical hypothyroidism complicating pregnancy.  Thyroid. 2002;  12 63-68
• 13 Negro R, Formoso G, Mangieri T et al. Levothyroxine treatment in euthyroid pregnant women with autoimmune thyroid disease: effects on obstetrical complications.  J Clin Endocrinol Metab. 2006;  91 2587-2591
• 14 Oates-Whitehead R M, Haas D M, Carrier J A. Progestogen for preventing miscarriage.  Cochrane Database Syst Rev. 2003;  (4) CD003511
• 15 Daya S. Efficacy of progesterone support for pregnancy in women with recurrent miscarriage. A meta-analysis of controlled trials.  Br J Obstet Gynaecol. 1989;  96 275-280
• 16 Nardo L G, Sallam H N. Progesterone supplementation to prevent recurrent miscarriage and to reduce implantation failure in assisted reproduction cycles.  Reprod Biomed Online. 2006;  13 47-57
• 17 Szekeres-Bartho J. Regulation of NK cell cytotoxicity during pregnancy.  Reprod Biomed Online. 2008;  16 211-217
• 18 Szekeres-Bartho J, Balasch J. Progestagen therapy for recurrent miscarriage.  Human Reprod update. 2008;  14 27-35
• 19 Bohlmann M K, Lüdders D W, Baumann K et al. Use of progestogen during pregnancy.  Gynäkol Endokrinol. 2008;  6 171-176
• 20 Rai R, Backos M, Rushworth F et al. Polycystic ovaries and recurrent miscarriage – a reappraisal.  Hum Reprod. 2000;  15 612-615
• 21 Craig L B, Ke R W, Kutteh W H. Increased prevalence of insulin resistance in women with a history of recurrent pregnancy loss.  Fertil Steril. 2002;  78 487-490
• 22 Jakubowicz D J, Iuorno M J, Jakubowicz S et al. Effects of metformin on early pregnancy loss in the polycystic ovary syndrome.  J Clin Endocrinol Metab. 2002;  87 524-529
• 23 Clifford K, Rai R, Watson H et al. Does suppressing luteinising hormone secretion reduce the miscarriage rate? Results of a randomised controlled trial.  BMJ. 1996;  312 1508-1511
• 24 Rey E, Kahn S K, David M et al. Thrombophilic disorders and fetal loss: a metaanalysis.  Lancet. 2003;  361 901-908
• 25 Pihusch R, Buchholz T, Lohse P et al. Thrombophilic gene mutations and recurrent spontaneous abortion: Prothrombin increases the risk in the first trimester.  Am J Reprod Immunol. 2001;  46 124-131
• 26 Brenner B, Nowak-Göttl U, Kosch A et al. Diagnostic studies for thrombophilia in women on hormonal therapy and during pregnancy, and children.  Arch Pathol Lab Med. 2002;  126 1296-1303
• 27 Buchholz T, Lohse P, Rogenhofer N et al. Polymorphisms in the ACE and PAI-1 genes are associated with recurrent spontaneous miscarriages.  Hum Reprod. 2003;  18 2473-2477
• 28 Menge S, Müller-Lantzsch C, Keck C et al. Recurrent spontaneous abortion: causes and therapeutic options.  Geburtsh Frauenheilk. 2004;  64 573-583
• 29 Brenner B, Sarig G, Weiner Z. Thrombophilic polymorphisms are common in women with fetal loss without apparent cause.  Thromb Haemost. 1999;  82 6-9
• 30 Makris M. Hyperhomocysteinemia and thrombosis.  Clin Lab Haematol. 2000;  22 133-143
• 31 Nelen W L, Blom H J, Steegers E A et al. Hyperhomocysteinemia and recurrent early pregnancy loss: a meta-analysis.  Fertil Steril. 2000;  74 1196-1199
• 32 Bohlmann M K, von Wolff M, Rossmann H et al. MTHFR-Polymorphismen und Homocysteinspiegel bei Paaren mit habituellen Aborten.  Arch Gyn Obstet. 2004;  270 FV-E1.2 S13
• 33 Ghosh K, Shetty S, Vora S et al. Successful pregnancy outcome in women with bad obstetric history and recurrent fetal loss due to thrombophilia: effect of unfractionated heparin and low-molecular weight heparin.  Clin Appl Thromb Hemost. 2008;  14 174-179
• 34 Gris J C, Mercier E, Quere I et al. Low-molecular weight heparin versus lowdose aspirin in women with one fetal loss and a constitutional thrombophilic disorder.  Blood. 2004;  103 3695-3699
• 35 Brenner B, Hoffman R, Carp H LIVE-ENOX Investigators et al. Efficacy and safety of two doses of enoxaparin in women with thrombophilia and recurrent pregnancy loss: the LIVE-ENOX study.  J Thromb Haemost. 2005;  3 227-229
• 36 Laskin C A, Spitzer K A, Clark C A et al. Low molecular weight heparin and aspirin for recurrent pregnancy loss: results from the randomized, controlled HepASA Trial.  J Rheumatol. 2009;  36 279-287
• 37 Badawy A M, Khiary M, Sherif L S et al. Low-molecular weight heparin in patients with recurrent early miscarriages of unknown aetiology.  J Obstet Gynaecol. 2008;  28 280-284
• 38 Rai R, Cohen H, Dave M et al. Randomised controlled trial of aspirin and aspirin plus heparin in pregnant women with recurrent miscarriage associated with phospholipid antibodies (or antiphospholipid antibodies).  BMJ. 1997;  314 253-257
• 39 Miyakis S, Lockshin M D, Atsumi T et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS).  J Thromb Haemost. 2006;  4 295-306
• 40 Heilmann L, v Tempelhoff G F, Pollow K. Antiphospholipid syndrome in obstetrics.  Clin Appl Thromb Hemost. 2003;  9 143-150
• 41 Empson M, Lassere M, Craig J C et al. Recurrent pregnancy loss with antiphospholipid antibody: a systematic review of therapeutic trials.  Obstet Gynecol. 2002;  99 135-144
• 42 Scholz C, Rogenhofer N, Jeschke U. Schwangerschaft und maternales Immunsystem.  Der Gynäkologe. 2009;  42 25-30
• 43 Wegmann T G, Lin H, Guilbert L. Bidirectional cytokine interactions in the maternal-fetal relationship: is successful pregnancy a TH2 phenomenon?.  Immunol Today. 1993;  14 353-356
• 44 Clark D A. Immunological factors in pregnancy wastage: fact or fiction.  Am J Reprod Immunol. 2008;  59 277-300
• 45 Tomczak S, Briese V, Kunkel S. Serum placental protein 14 (PP14) levels in patients with threatened abortion.  Arch Gynecol Obstet. 1996;  258 165-169
• 46 Moffett-King A. Natural killer cells and pregnancy.  Nat Rev Immunol. 2002;  2 656-663
• 47 Quenby S, Farquharson R. Uterine natural killer cells, implantation failure and recurrent miscarriage.  Reprod Biomed Online. 2006;  13 24-28
• 48 Shakhar K, Rosenne E, Loewenthal R et al. High NK cell activity in recurrent miscarriage: what are we really measuring?.  Hum Reprod. 2006;  21 2421-2425
• 49 Salamonsen L A, Hannan N J, Dimitriadis E. Cytokines and chemokines during human embryo implantation: roles in implantation and early placentation.  Sem Reprod Med. 2007;  25 437-444
• 50 Okamoto N, Uchida A, Takakura K. Suppression by human placenta protein 14 of natural killer cell activity.  Am J Reprod Immunol. 1991;  26 137-142
• 51 Tulppala M, Julkunen M, Tiitinen A. Habitual abortion is accompanied by low serum levels of placental protein 14 in the luteal phase of the fertile cycle.  Fertil Steril. 1995;  63 792-795
• 52 Toth B, Roth K, Kunert-Keil C. Glycodelin protein and mRNA is downregulated in human first trimester abortion and partially upregulated in mole pregnancy.  J Histochem Cytochem. 2008;  56 477-485
• 53 van Mourik M S M, Heijnen C J, Macklon N S. Embryonic implantation: cytokines, adhesion molecules and immune cells in establishing an implantation environment.  J Leukocyt Biol. 2009;  85 4-19
• 54 Scott J R. Immunotherapy for recurrent miscarriage.  Cochrane Database Syst Rev. ;  (1) CD000112
• 55 Rai R. Should immunotherapy be used in RPL? – Against. Carp HJA Recurrent Pregnancy Loss. Causes, Controversies and Treatment. London; Informa Healthcare 2007: 189-192
• 56 Porter T F, LaCoursiere Y, Scott J R. Immunotherapy for recurrent miscarriage (review).  Cochrane Database Syst Rev (online). 2006;  (2) CD000112
• 57 Heilmann L, Dietl J, Ludwig M et al. Diagnostik und Therapie beim wiederholten Spontanabort. AWMF-Leitlinien-Register Nr. 015/050. 
• 58 Stricker R B, Winger E E. Update on treatment of immunologic abortion with low-dose intravenous immunoglobulin.  Am J Reprod Immunol. 2005;  54 390-396
• 59 Christiansen O B, Pedersen B, Rosgaard A et al. A randomized, double-blind, placebo-controlled trial of intravenous immunoglobulin in the prevention of recurrent miscarriage: evidence for a therapeutic effect in women with secondary recurrent miscarriage.  Human Reprod. 2002;  17 809-816
• 60 Christiansen O B, Nielsen H S. Intravenous immunoglobulin in the prevention of recurrent miscarriage: does it work?.  Chem Immunol Allergy. 2005;  88 117-127
• 61 Hutton B, Sharma R, Fergusson D et al. Use of intravenous immunoglobulin for treatment of recurrent miscarriage: a systematic review.  BJOG. 2007;  114 134-142
• 62 Kiprov D D, Nachtigall R D, Weaver R C et al. The use of intravenous immunoglobulin in recurrent pregnancy loss associated with combined alloimmune and autoimmune abnormalities.  Am J Reprod Immunol. 1996;  36 228-234